Lead Product(s): Diclofenac conjugated sodium hyaluronate
Therapeutic Area: Musculoskeletal
Highest Development Status: Phase III Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 01, 2020
The companies will jointly develop SI-613 in China for knee osteoarthritis. After obtaining approval, Seikagaku will supply products to Eisai, and Eisai will be responsible for distribution.